HK1154211A1 - 預防和減少失血和炎症反應 - Google Patents

預防和減少失血和炎症反應

Info

Publication number
HK1154211A1
HK1154211A1 HK11108085.6A HK11108085A HK1154211A1 HK 1154211 A1 HK1154211 A1 HK 1154211A1 HK 11108085 A HK11108085 A HK 11108085A HK 1154211 A1 HK1154211 A1 HK 1154211A1
Authority
HK
Hong Kong
Prior art keywords
phe
cys
glu
ala
gly
Prior art date
Application number
HK11108085.6A
Other languages
English (en)
Inventor
Robert Charles Ladner
Arthur C Ley
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of HK1154211A1 publication Critical patent/HK1154211A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
HK11108085.6A 2002-06-07 2008-12-31 預防和減少失血和炎症反應 HK1154211A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38723902P 2002-06-07 2002-06-07
US40700302P 2002-08-28 2002-08-28

Publications (1)

Publication Number Publication Date
HK1154211A1 true HK1154211A1 (zh) 2012-04-13

Family

ID=29739936

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11108085.6A HK1154211A1 (zh) 2002-06-07 2008-12-31 預防和減少失血和炎症反應
HK08114131.3A HK1119955A1 (en) 2002-06-07 2008-12-31 Modified kunitz domain polypeptide
HK11108870.5A HK1154513A1 (zh) 2002-06-07 2008-12-31 改造的庫尼茨結構域的多肽和它們用於減少局部失血或與手術過程相關的全身炎性反應病發

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK08114131.3A HK1119955A1 (en) 2002-06-07 2008-12-31 Modified kunitz domain polypeptide
HK11108870.5A HK1154513A1 (zh) 2002-06-07 2008-12-31 改造的庫尼茨結構域的多肽和它們用於減少局部失血或與手術過程相關的全身炎性反應病發

Country Status (13)

Country Link
US (13) US7064107B2 (zh)
EP (4) EP1531791B1 (zh)
JP (3) JP2005534647A (zh)
AT (2) ATE477020T1 (zh)
AU (3) AU2003243394B2 (zh)
CA (1) CA2488558C (zh)
CY (1) CY1112228T1 (zh)
DE (1) DE60333758D1 (zh)
DK (4) DK1531791T3 (zh)
ES (4) ES2348230T3 (zh)
HK (3) HK1154211A1 (zh)
PT (4) PT1941867E (zh)
WO (1) WO2003103475A2 (zh)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
WO2002011495A2 (en) 2000-07-31 2002-02-07 Harman International Industries, Inc. Loudspeaker coil suspension system
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
AU2003243394B2 (en) * 2002-06-07 2008-06-12 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2386310B1 (en) * 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
DE602004030264D1 (de) * 2003-09-12 2011-01-05 Z Medica Corp Teilweise hydriertes hämostatisches mittel
US20060177971A1 (en) * 2004-01-13 2006-08-10 Jsr Corporation Anisotropically conductive connector, production process thereof and application product thereof
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005318464B2 (en) * 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
US20060178609A1 (en) 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots
US11167058B2 (en) 2005-02-15 2021-11-09 Virginia Commonwealth University Hemostasis of wound having high pressure blood flow
WO2007062676A1 (en) 2005-12-01 2007-06-07 B.R.A.H.M.S. Aktiengesellschaft Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
LT1854477T (lt) * 2006-03-16 2016-12-12 Dyax Corp. Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui
PL2374472T3 (pl) 2006-03-16 2018-11-30 Dyax Corp. Kompozycje i sposoby leczenia zaburzeń okulistycznych
US8938898B2 (en) * 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US7968114B2 (en) 2006-05-26 2011-06-28 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US8202532B2 (en) 2006-05-26 2012-06-19 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20080085300A1 (en) * 2006-10-06 2008-04-10 Z-Medica Corporation Hemostatic compositions and method of manufacture
US9345457B2 (en) 2006-12-13 2016-05-24 Devicor Medical Products, Inc. Presentation of biopsy sample by biopsy device
AU2008289005A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2008288772A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009032884A1 (en) * 2007-09-05 2009-03-12 Z-Medica Corporation Wound healing with zeolite-based hemostatic devices
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
EP2347778A1 (de) 2010-01-25 2011-07-27 ECP Entwicklungsgesellschaft mbH Fluidpumpe mit einem radial komprimierbaren Rotor
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
AU2012267546B2 (en) * 2011-06-10 2015-12-24 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
EP2726153B1 (en) 2011-06-29 2018-03-28 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
PT2780717T (pt) 2011-11-16 2017-02-16 Sphingotec Gmbh Ensaios de adrenomedulina e processos para a determinação de adrenomedulina madura
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
WO2013072513A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
ES2938653T3 (es) 2011-11-16 2023-04-13 Adrenomed Ag Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda
AU2012338734B2 (en) 2011-11-16 2017-08-24 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
KR102047443B1 (ko) 2011-11-16 2019-11-25 아드레노메드 아게 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
BR112014031439A8 (pt) 2012-06-22 2023-01-31 Z Medica Llc Dispositivos e curativos hemostáticos e para feridas e processos para produzir dispositivo hemostático e para tratar feridas
RU2679913C2 (ru) 2012-10-02 2019-02-14 Сфинготек Гмбх Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
JP6430962B2 (ja) 2013-01-08 2018-11-28 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 心血管系疾患発症リスクの予測的マーカーとしての成長ホルモンの空腹時レベル
EP3470837A1 (en) 2013-01-20 2019-04-17 Dyax Corp. Treatment of pkal-mediated disorders
PT2948479T (pt) 2013-01-20 2018-11-14 Dyax Corp Avaliação e tratamento de distúrbios mediados por bradicinina
ES2830036T3 (es) 2013-03-20 2021-06-02 Sphingotec Gmbh Adrenomedulina para guiar una terapia de disminución de la presión sanguínea
AU2014312196C1 (en) 2013-08-28 2019-12-19 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
WO2015061182A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
IL289514B2 (en) 2013-10-21 2024-01-01 Takeda Pharmaceuticals Co Tests to determine system biomarkers for plasma kallikrein
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3862362A3 (en) 2014-05-01 2021-10-27 Ionis Pharmaceuticals, Inc. Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
US20160097781A1 (en) 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
EP3286226A4 (en) 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
CN107667294B (zh) 2015-04-24 2021-12-17 思芬构技术有限公司 用于预测慢性肾病发生风险的方法
IL258637B2 (en) 2015-10-19 2024-10-01 Dyax Corp An immunoassay for the detection of high molecular weight cleaved kininogen
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112018071583A2 (pt) 2016-04-21 2019-02-12 Sphingotec Therapeutics Gmbh métodos para determinar dpp3 e métodos terapêuticos
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
MX2019000003A (es) 2016-07-08 2019-08-29 Sphingotec Gmbh Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.
KR102464380B1 (ko) 2016-09-16 2022-11-07 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
CN109716138B (zh) 2016-09-16 2023-10-03 武田药品工业株式会社 用于接触活化系统相关的疾病的蛋白生物标记
MX2019002929A (es) 2016-09-16 2019-07-15 Dyax Corp Biomarcadores de arn para angioedema hereditario.
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
BR112019011713A2 (pt) 2016-12-16 2019-10-15 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma
EP3631459A1 (en) 2017-05-30 2020-04-08 SphingoTec GmbH A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
CA3076691A1 (en) 2017-09-25 2019-03-28 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
US20220268761A1 (en) 2017-10-18 2022-08-25 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
WO2019081504A1 (en) 2017-10-24 2019-05-02 Sphingotec Gmbh SENENOPROTEIN P FOR PREDICTING A FIRST CARDIOVASCULAR EVENT
JP7424972B2 (ja) 2017-10-25 2024-01-30 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
MA53490A (fr) 2018-08-30 2022-05-04 Takeda Pharmaceuticals Co Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire
US20220043005A1 (en) 2018-12-20 2022-02-10 Sphingotec Gmbh Selenoprotein p in heart failure
WO2020128039A2 (en) 2018-12-21 2020-06-25 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
KR20210142006A (ko) 2019-03-14 2021-11-23 다케다 파머수티컬 컴패니 리미티드 유전성 혈관부종 발작의 치료를 위한 혈장 칼리크레인 저해제 및 이의 용도
MX2022001944A (es) 2019-08-15 2022-03-11 Sphingotec Gmbh Un metodo para diagnosticar o monitorear la funcion renal o diagnosticar la disfuncion renal en pacientes pediatricos.
RU2712629C1 (ru) * 2019-08-27 2020-01-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных ишемической болезнью сердца в сочетании с постинфарктной аневризмой левого желудочка
CN114556100A (zh) 2019-08-30 2022-05-27 4Teen4制药有限公司 用于治疗休克的疗法指引和/或疗法监测
JP2023510854A (ja) 2020-01-13 2023-03-15 武田薬品工業株式会社 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
EP4111204A1 (en) 2020-02-27 2023-01-04 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
MX2022010564A (es) 2020-02-27 2022-11-30 Adrenomed Ag Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque.
CA3168978A1 (en) 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP4121772A1 (en) 2020-03-16 2023-01-25 sphingotec GmbH Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
US20230213519A1 (en) 2020-03-16 2023-07-06 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
US20230174674A1 (en) 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
JP2024526081A (ja) 2021-06-18 2024-07-17 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 敗血症及び敗血症性ショックを予測する方法
KR20240041912A (ko) 2021-06-29 2024-04-01 베리솔 게엠베하 체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
WO2024003617A2 (en) 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
WO2024194276A1 (en) 2023-03-17 2024-09-26 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT275583B (de) 1964-03-04 1969-10-27 Plasser Bahnbaumasch Franz Profilfreie Maschine zum Reinigen des Eisenbahnbettungsschotters
BR6915369D0 (pt) 1969-02-27 1973-03-13 Bayer Ag Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
CA1113397A (en) * 1977-11-09 1981-12-01 Peter F.R. Lunn Aqueous persulphate and percarbonate composition for bleaching hair
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
AT359653B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US4299537A (en) * 1979-06-19 1981-11-10 Evans Frederick C Interlinked variable-pitch blades for windmills and turbines
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
AU560584B2 (en) 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US4931385A (en) 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
JPH0623113B2 (ja) 1986-01-31 1994-03-30 浩 前田 癌性胸・腹水貯留抑制剤
EP0255011A3 (en) 1986-07-29 1988-11-23 Miles Inc. Human inter-alpha-trypsin inhibitor gene
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
EP0332640A1 (en) 1986-11-17 1989-09-20 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
EP0285123A3 (en) 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE114332T1 (de) 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5278285A (en) * 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
IL99585A0 (en) 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
EP0486001A1 (en) 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Recombinant urinary trypsin inhibitor fragments and drug composition
US20030223977A1 (en) * 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993009233A2 (en) 1991-10-31 1993-05-13 The Salk Institute Biotechnology/Industrial Associates Inc. Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1994001461A1 (en) * 1992-07-13 1994-01-20 Corvas International, Inc. BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa
AU5684594A (en) 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
US5426224A (en) 1993-03-18 1995-06-20 The University Of North Carolina At Chapel Hill Mammalian DNA topoisomerase II inhibitor and method
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT737207E (pt) * 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
ES2227545T3 (es) * 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6008196A (en) * 1994-06-02 1999-12-28 Hoechst Marion Roussel, Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
NZ296648A (en) * 1994-10-18 2001-05-25 Corvas Int Inc Nematode-extracted serine protease inhibitors and anticoagulant proteins
US6159938A (en) * 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
ATE532530T1 (de) * 1994-12-12 2011-11-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und/oder spasmen an einer gefässstruktur
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DK0813525T3 (da) * 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5804376A (en) * 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
CA2220497A1 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JPH0959838A (ja) 1995-08-24 1997-03-04 Kuraray Co Ltd 紡績糸
CN1200036A (zh) 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
CA2232834A1 (en) * 1995-09-21 1997-03-27 University Of Utah Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US5824870A (en) 1995-11-06 1998-10-20 Baszczynski; Chris Commercial production of aprotinin in plants
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
KR100356956B1 (ko) 1996-03-11 2003-03-15 베이어 코오포레이숀 사람비쿠닌
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
JP3657700B2 (ja) * 1996-06-18 2005-06-08 新日本石油化学株式会社 カサ高性不織布の製造方法
US5869637A (en) * 1996-07-22 1999-02-09 Incyte Pharmaceuticals, Inc. Human Kallikrein
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
AU6042298A (en) * 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5786238A (en) * 1997-02-13 1998-07-28 Generyal Dynamics Information Systems, Inc. Laminated multilayer substrates
US5962300A (en) * 1997-03-26 1999-10-05 Incyte Pharmaceuticals, Inc. Human kallikrein
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP1027054A4 (en) 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
CA2316834C (en) * 1998-01-07 2006-01-03 Shearwater Polymers, Inc. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
DK1061954T3 (da) * 1998-03-12 2004-10-18 Nektar Therapeutics Al Corp Polyethylenglycolderivater med proximale reaktive grupper
DK0985697T3 (da) * 1998-03-24 2006-05-15 Nof Corp Oxiranderivater og fremgangsmåde til fremstilling deraf
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
US6001596A (en) * 1998-05-07 1999-12-14 Incyte Pharmaceuticals, Inc. Growth-associated protease inhibitor heavy chain precursor
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
EP1082431A2 (en) * 1998-06-03 2001-03-14 Scios Inc. Protease inhibitor peptides
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2361190T3 (es) * 1998-08-06 2011-06-14 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
AU5805499A (en) 1998-09-03 2000-03-27 Zymogenetics Inc. Kunitz domain polypeptide zkun6
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CA2352538A1 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US20030012969A1 (en) * 1999-04-06 2003-01-16 Clark Bert Thomas Soluble membrane strengthened paper products
IL145894A0 (en) 1999-04-29 2002-07-25 Novo Nordisk As Use of heparin-binding antagonists in the inhibition of bradykinin release
US6605316B1 (en) 1999-07-31 2003-08-12 The Regents Of The University Of California Structures and fabrication techniques for solid state electrochemical devices
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US6348558B1 (en) * 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
EP1259563B2 (en) * 1999-12-22 2016-08-10 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
US6544760B2 (en) * 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en) * 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001068707A1 (en) 2000-03-13 2001-09-20 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CN1331213A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人大蛋白10.01和编码这种多肽的多核苷酸
DE10034357C1 (de) 2000-07-14 2001-12-13 Elotherm Gmbh Verfahren und Vorrichtung zum Härten von Flächen an Bauteilen
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
ES2203601T3 (es) * 2000-10-31 2004-04-16 Debiopharm S.A. Suspension de una proteina de epi-hne, metodo para su preparacion, un aerosol en forma de polvo seco derivado de la misma, compuestos farmaceuticos que comprenden dicha suspension o dicho aerosol y sus utilizaciones.
US20030113726A1 (en) 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
EP1392350A2 (en) 2001-05-11 2004-03-03 Aradigm Corporation Optimization of the molecular properties and formulation of proteins delivered by inhalation
CN101045166A (zh) 2001-05-21 2007-10-03 耐科塔医药公司 化学修饰胰岛素的肺部给药
US20040152633A1 (en) * 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
AU2002358921A1 (en) 2001-07-10 2003-04-28 Omnio Ab Novel drug targets for arthritis
CN100366965C (zh) 2001-07-10 2008-02-06 日本电产三协株式会社 阀驱动设备
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2005516607A (ja) 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
AU2003231865A1 (en) 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
AU2003243394B2 (en) * 2002-06-07 2008-06-12 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
PL375254A1 (en) * 2002-07-24 2005-11-28 F.Hoffmann-La Roche Ag Pegylated t20 polypeptide
PL375265A1 (en) * 2002-07-24 2005-11-28 F.Hoffmann-La Roche Ag Polyalkylene glycol acid additives
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
DE602004031589D1 (de) * 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
JP2006515882A (ja) 2003-01-08 2006-06-08 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
JP2008500942A (ja) 2003-01-08 2008-01-17 カイロン コーポレイション 組織因子経路インヒビターまたは組織因子経路インヒビター改変体を含有する安定化凍結乾燥組成物
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005003150A2 (en) 2003-07-02 2005-01-13 Emory University Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
US7273610B2 (en) * 2003-08-14 2007-09-25 Dyax Corp. Endotheliase-2 ligands
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US8114123B2 (en) 2003-09-19 2012-02-14 St. Jude Medical, Inc. Apparatus and methods for tissue gathering and securing
EP1689401A1 (en) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Method for reducing pain
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
WO2005041631A2 (en) * 2003-10-21 2005-05-12 Dyax Corp. Endotheliase-1 ligands
EP1713929A2 (en) 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060111296A1 (en) 2004-11-22 2006-05-25 Dyax Corp. Plasmin-inhibitory therapies
ITMI20042442A1 (it) 2004-12-21 2005-03-21 Aliveris S R L Paste alimentari con migliorate caratteristiche di digeribilita'
AU2005318464B2 (en) 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
NZ591178A (en) 2005-05-04 2012-06-29 Zealand Pharma As Glucagon-like-peptide-2 (glp-2) analogues
US20070079096A1 (en) 2005-09-30 2007-04-05 Chih-Wei Chen Data storage unit access authorization table automatic rebuilding method and system
US7583040B2 (en) 2005-09-30 2009-09-01 9141-0720 Quebec Inc. Motorized closure operating device with electronic control system
DK1981519T3 (en) * 2005-12-29 2018-02-19 Dyax Corp protease inhibition
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
LT1854477T (lt) 2006-03-16 2016-12-12 Dyax Corp. Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui
US20080031426A1 (en) 2006-06-27 2008-02-07 Weeks Walter L Audio, video, and navigational law enforcement system and method
EP1873344A1 (de) 2006-06-30 2008-01-02 Sika Technology AG Mittels Silikon agedichtete Verklebung
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions
AU2008289005A1 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2008288772A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009102927A1 (en) 2008-02-13 2009-08-20 Dyax Corp. Improved methods for producing specific binding pairs
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
DE102008033095A1 (de) 2008-07-15 2010-01-28 Uhde Gmbh Vorrichtung zur Schlackeabführung aus einem Kohlevergasungsreaktor
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
EP3470837A1 (en) 2013-01-20 2019-04-17 Dyax Corp. Treatment of pkal-mediated disorders
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema

Also Published As

Publication number Publication date
US20110086801A1 (en) 2011-04-14
US20080131426A1 (en) 2008-06-05
EP1531791B1 (en) 2010-08-11
PT1531791E (pt) 2010-12-16
AU2011201811A1 (en) 2011-05-19
US20190247477A1 (en) 2019-08-15
ES2559927T3 (es) 2016-02-16
ES2348230T3 (es) 2010-12-01
EP1941867B1 (en) 2011-10-12
US20040038893A1 (en) 2004-02-26
WO2003103475A2 (en) 2003-12-18
US20080076712A1 (en) 2008-03-27
HK1154513A1 (zh) 2012-04-27
CA2488558C (en) 2013-08-20
US20080260752A1 (en) 2008-10-23
EP1941867A1 (en) 2008-07-09
US8710007B2 (en) 2014-04-29
EP2311432A1 (en) 2011-04-20
US20080200646A1 (en) 2008-08-21
JP5249251B2 (ja) 2013-07-31
DE60333758D1 (de) 2010-09-23
PT2311432E (pt) 2015-02-09
AU2008202377B2 (en) 2011-05-12
ES2528254T3 (es) 2015-02-05
DK1531791T3 (da) 2010-11-01
US8124586B2 (en) 2012-02-28
PT1941867E (pt) 2012-02-16
US20160361395A1 (en) 2016-12-15
AU2003243394B2 (en) 2008-06-12
US10245307B2 (en) 2019-04-02
JP2010155842A (ja) 2010-07-15
AU2008202377A1 (en) 2008-06-19
CA2488558A1 (en) 2003-12-18
WO2003103475A3 (en) 2005-03-10
DK1941867T3 (da) 2012-01-02
US9480733B2 (en) 2016-11-01
US7064107B2 (en) 2006-06-20
ATE477020T1 (de) 2010-08-15
EP2298278B1 (en) 2015-11-11
ES2372978T3 (es) 2012-01-30
EP2311432B1 (en) 2014-12-24
EP1531791A2 (en) 2005-05-25
US20140349940A1 (en) 2014-11-27
JP2005534647A (ja) 2005-11-17
ATE528014T1 (de) 2011-10-15
US20080064637A1 (en) 2008-03-13
EP2298278A1 (en) 2011-03-23
US7851442B2 (en) 2010-12-14
CY1112228T1 (el) 2015-12-09
AU2003243394A1 (en) 2003-12-22
JP2013049698A (ja) 2013-03-14
PT2298278E (pt) 2016-02-25
US11344610B2 (en) 2022-05-31
US20060194727A1 (en) 2006-08-31
US20080152656A1 (en) 2008-06-26
DK2298278T3 (en) 2016-02-01
EP1531791A4 (en) 2008-05-21
US20090082267A1 (en) 2009-03-26
DK2311432T3 (en) 2015-02-02
HK1119955A1 (en) 2009-03-20
US7811991B2 (en) 2010-10-12

Similar Documents

Publication Publication Date Title
HK1154211A1 (zh) 預防和減少失血和炎症反應
NO942553L (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
AU1633200A (en) Human parathyroid hormone modifications, preparation and use
DE69128664D1 (de) CNP-Gen und Vorläuferprotein aus Schwein
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
YU29596A (sh) Genski proizvodi koji regulišu gojaznost
WO2004014937A3 (en) Thrombin peptide derivatives
NZ334714A (en) Liver proteins as agents against autoimmune diseases
CA2077590A1 (en) Recombinant dna coding for a protein with endochitinase activity
ATE124955T1 (de) Substrat-peptide.
AU8302791A (en) Recombinant gene coding for a protein having an endochitinase activity
EP1225184A4 (en) HUMAN ANTITHROMBIN VARIANTS
CY1115911T1 (el) Τροποποιημενα πολυπεπτιδια περιοχης kunitz και η χρηση τους στην μειωση της ισχαιμιας ή της εκκινησης μιας συστημικης φλεγμονωδους ανταποκρισης που σχετιζεται με μια χειρουργικη επεμβαση
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
WO1999057262A3 (de) An metallionen bindendes peptid
WO2001080811A3 (en) Mmp-2 propeptide for use as antiangiogenic or antitumor agent
TH56074A3 (th) ตัวยับยั้ง อัลฟาv เบตา6 อินทีกริน

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM DYAX CORPORATION TO DYAX CORP

PE Patent expired

Effective date: 20230601